Aripiprazole Lauroxil
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Aripiprazole Lauroxil
- Aripiprazole Lauroxil: From Antipsychotic Therapy to Retinal Dystrophy with or without Extraocular Anomalies
Aripiprazole Lauroxil: From Antipsychotic Therapy to Retinal Dystrophy with or without Extraocular Anomalies
One-Sentence Summary
Aripiprazole lauroxil is a long-acting injectable prodrug of aripiprazole, an antipsychotic that acts on dopamine and serotonin receptors. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but 0 clinical trials and 0 drug-specific publications currently support this direction. It is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 5 (4 entries under NDA207533, 1 under NDA209830) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Aripiprazole lauroxil is a prodrug of aripiprazole, a D2/5-HT1A partial agonist and 5-HT2A antagonist. The Evidence Pack does not list an original indication or a detailed mechanism of action, so the mechanism cannot be cross-checked against the original use.
No established link connects this mechanism to the predicted disease. Retinal dopamine signaling exists, but nothing ties it to inherited retinal dystrophy with extraocular anomalies, which is genetic and structural. The high score (99.99%) comes from graph-based prediction alone.
The drug is also an extended-release intramuscular injectable, and no ocular delivery route has been evaluated.
Eight other predicted indications share the same weakness: hydranencephaly, Charcot-Marie-Tooth disease type 1G, a congenital disorder of glycosylation, a polymicrogyria syndrome, syndromic myopia, two X-linked myopias, and atypical glycine encephalopathy. All have scores above 99.98%, no trials or literature, and no plausible mechanism. The myopia entries have only a speculative rationale, based on dopamine’s role in eye-growth control in animal models.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The 14 retrieved publications were matched to the disease name, not to the drug. None studies aripiprazole lauroxil or aripiprazole, so they describe the disease area only and do not support efficacy. Ten are listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9416661 | 1997 | Review | Semin Ultrasound CT MR | Overview of orbital infections; sinusitis is the most common cause |
| 20127583 | 2010 | Review | Semin Neurol | Systematic approach to evaluating diplopia |
| 38321238 | 2024 | Review | Pediatr Radiol | Differential diagnosis and imaging of pediatric ocular pathologies |
| 38249493 | 2023 | Review | Taiwan J Ophthalmol | Congenital anomalies of lens shape, size and position |
| 22241537 | 2012 | Review | Klin Monbl Augenheilkd | Congenital ptosis and its associations with refractive errors |
| 7035111 | 1981 | Review | Doc Ophthalmol | Wagner-Stickler syndrome complex: vitreoretinal degeneration with extraocular manifestations |
| 30196776 | 2018 | Review | J Binocul Vis Ocul Motil | Congenital cranial dysinnervation disorders causing ophthalmoplegia |
| 24932988 | 2014 | Review | Am J Ophthalmol | Pathogenesis and treatment of maculopathy with cavitary optic disc anomalies |
| 19826317 | 2009 | Review | Optom Vis Sci | Single case of synergistic divergence in congenital fibrosis of extraocular muscles |
| 109006 | 1979 | Case report | Am J Ophthalmol | Two patients with unilateral cryptophthalmia |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA207533 (4 entries) | ARISTADA | Injection, suspension, extended release | Not listed in the source data |
| NDA209830 | ARISTADA INITIO | Injection, suspension, extended release | Not listed in the source data |
The manufacturer for all entries is Alkermes, Inc.
Safety Considerations
Please refer to the package insert for safety information. The Evidence Pack has no warnings or contraindications, and the drug interaction query returned no results.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a graph score alone, with no clinical trials, no drug-specific literature and no plausible mechanistic link to a genetic retinal disease. Package insert safety data are also missing, which blocks safety screening.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (download and parse the label PDF)
- Mechanism of action data from DrugBank, followed by a mechanism-level review of retinal dopamine and D2 signaling
- Any preclinical evidence on aripiprazole in retinal degeneration models
- An assessment of whether an extended-release intramuscular injectable is compatible with ocular delivery
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.